EPHA2 and cancer: These pH-sensitive LYTACs (pH_LYTACs) induced more potent degradation of EphA2 in two different cancer cell lines, HCT116 and MDA-MB-231, as assessed by cell-surface staining and western blot (Fig. 4C, Fig. S12a), with dose-dependent degradation (Fig. 4D).